Nature Clinical Practice Gastroenterology & Hepatology
Interferon-based Therapy for Chronic Hepatitis C: Current and Future Perspectives CME

Disclosures

Release Date: October 9, 2008; Valid for credit through October 9, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Interferon-based Therapy for Chronic Hepatitis C: Current and Future Perspectives
    Stefan Zeuzem, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify outcomes of treatment for chronic hepatitis C virus (HCV) infection
  2. Specify the recommended duration of treatment for chronic HCV infection
  3. Describe how treatment for chronic HCV infection may be altered on the basis of individual patient characteristics
  4. Describe potential new treatments for chronic HCV infection
Authors and Disclosures

Stefan Zeuzem, MD
Disclosure: Stefan Zeuzem, MD, has disclosed that he is a clinical investigator and consultant for and received grant/research support from Debiopharm, Gilead, Human Genome Sciences, InterMune, Novartis, Pharmasset, Roche, Schering-Plough, Tibotec, Vertex, and Wyeth. Dr. Zeuzem has also disclosed that he is on the speakers’ bureau for Novartis, Roche, and Schering-Plough.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.


Natalie Wood
Disclosure: Natalie Wood has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.